The role of tumor necrosis factor in the pathophysiology of heart failure

Journal of the American College of Cardiology

Volumn 35, Issue 3, 2000, Pages 537-544

  Feldman, Arthur M ^a   Combes, Alain ^a   Wagner, Daniel ^a   Kadakomi, Toshiaki ^a   Kubota, Toru ^a   You Li, Yun ^a   McTiernan, Charles ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE; ETANERCEPT; ISOPRENALINE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; RECOMBINANT RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD LEVEL; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; DISEASE SEVERITY; HEART FAILURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034162801     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00600-2     Document Type: Article

References (100)

1. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 72:1975;3666-3670.
2. Beutler B., Mahoney J., Le Trang N., Pekala P., Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone, secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 161:1985;984-995.
3. Evans R.D., Argiles J.M., Williamson D.H. Metabolic effects of tumor necrosis factor-alpha (cachectin) and interleukin-1. Clin Sci. 77:1989;357-364.
4. Caput D., Beutler B., Hartog K., Thayer R., Brown-Shimer S., Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA. 83:1986;1670-1674.
5. Pennica D., Hayflick J.S., Bringham T.S., Palladino M.A., Goeddal D.V. Cloning and expression in E coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA. 82:1985;6060-6064.
6. Kriegier M., Perez C., DeFay K., Albert I., Lu S.D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein ramifications for the complex physiology of TNF. Cell. 53:1988;45-53.
7. Tracey K.J., Vlassara H., Cerami A. Cachectin/tumor necrosis factor. Lancet. 1:1989;1122-1126.
8. Beutler B., van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 264:1994;667-668.
9. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 10:1992;411-452.
10. Dembic Z., Loetscher H., Gubler U., et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine. 2:1990;231-237.
11. Bachmaier K., Pummerer C., Kozieradzki I., et al. Low-molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart disease. Circulation. 95:1997;655-661.
12. Olsson I., Lantz M., Nilsson E., et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol. 42:1989;270-275.
13. Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 265:1990;1531-1536.
14. Brakebusch C., Nophar Y., Kemper O., Engelmann H. Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J. 11:1992;943-950.
15. Seckinger P., Isaaz S., Dayer J.M. A human inhibitor of tumor necrosis factor alpha. J Exp Med. 167:1988;1511-1516.
16. Vilcek J., Lee T.H. Tumor necrosis factor. J Biol Chem. 266:1991;7313-7316.
17. Pfeffer K., Matsuyama T., Kuendig T.M., et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to monocytogenes infection. Cell. 73:1993;457-467.
18. Djeu J.Y., Blanchard D.K., Richards A.L., Friedman H. Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Exp Med. 141:1988;4047-4052.
19. Kwak E.L., Larochelle D.A., Beaumont C., Torti S.V., Torti F.M. Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem. 270:1995;15285-15293.
20. Dinarello C.A., Cannon J.G., Wolff S.M., et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 163:1986;1433-1450.
21. Larrick J.W., Wright S.C. Cytotoxic mechanism of tumor necrosis factor-alpha. FASEB J. 4:1990;3215-3223.
22. Old L.J. Tumor necrosis factor (TNF). Science. 230:1985;630-632.
23. Malik S.T.A., Griffin D.B., Fiers W., Balkwill F.R. Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int J Cancer. 44:1989;918-925.
24. Malik S.T.A., Naylor M.S., East N., Oliff A., Balkwill F.R. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer. 26:1990;1031-1034.
25. Naylor M.S., Stamp G.W.H., Foulkes W.D., Eccles D., Balkwill F.R. Tumor necrosis factor and its receptors in human ovarian cancer. J Clin Invest. 91:1993;2194-2206.
26. Manicourt D.H., Triki R., Fukuda K., Devogelaer J.P., Nagant de Deuxchaisnes C., Thonar E.J. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum. 36:1993;490-499.
27. Kupferminc M.J., Peaceman A.M., Wigton T.R., Rehnberg K.A., Socol M.L. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol. 170:1994;1752-1757.
28. Harel Y., Silva M., Giroir B., Weinberg A., Cleary T.B., Beutler B. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest. 92:1992;2110-2116.
29. Wu C.J., Lovett M., Wong-Lee J., et al. Cytokine gene expression in rejecting cardiac allografts. Transplantation. 54:1992;326-332.
30. Sandborn W.J. A controlled trial of antitumor necrosis factor alpha antibody for Crohn's disease. Gastroenterology. 113:1997;1042-1043.
31. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
32. Testa M., Yeh M., Lee P., et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 28:1996;964-971.
33. Torre-Amione G., Kapadia S., Benedict C., Oral Y., Young J.B., Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 27:1996;1201-1206.
34. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 92:1995;1479-1486.
35. MacGowan G., Mann D.L., Kormos R.L., Feldman A.M., Murali S. Circulating interleukin-6 in severe congestive heart failure. Am J Cardiol. 79:1997;1128-1131.
36. Matsumori A., Yamada T., Suzuki H., Matoba Y., Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
37. Suffredini A.F., Fromm R.E., Parker M.M., et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 321:1989;280-287.
38. Torre-Amione G., Kapadia S., Lee J., Durand J.B., Bies R.D., Young J.B.M.D.L. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 93:1996;704-711.
39. Finkel M.S., Oddis C.V., Jacob T.D., Watkins S.C., Hattler B.G., Simmons R.L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
40. Yokoyama T., Vaca L., Rossen R.D., Durante W., Hazarika P., Mann D.L. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312.
41. Eichenholz P.W., Eichacker P.Q., Hoffman W.D., Banks S.M., Parrillo J.E.D.R., Natanson C. Tumor necrosis factor challenges in canines patterns of cardiovascular dysfunction. Am J Physiol. 263:1992;H668-H675.
42. McTiernan C.F., Lemster B.H., Frye C.S., Combes A., Feldman A.M. Interleukin-1B phospholamban gene expression in cultured cardiomyocytes. Circulation Res. 81:1997;493-503.
43. Gulick T., Chung M.K., Pieper S.J., Lange L.G., Schreiner G.F. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA. 86:1989;6753-6757.
44. Chung M.K., Gulick T.S., Rotondo R.E., Schreiner G.F., Lange L.G. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res. 67:1990;753-763.
45. Li Y.Y., McTiernan C.F., Feldman A.M. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res. 42:1999;162-172.
46. Yokoyama T., Nakano M., Bednarczyk J., McIntyre B.W., Entman M., Mann D.L. Tumor Necrosis Factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 95:1996;1247-1252.
47. Oral H., Dorn G.W., Mann D.L. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem. 272:1997;4836-4842.
48. Bozkurt B., Kribbs S.B., Clubb F.J. Jr., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:1998;1382-1391.
49. Kubota T., McTiernan C.F., Frye C.S., Demetris A.J., Feldman A.M. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Cardiac Failure. 3:1997;117-124.
50. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circulation Res. 81:1997;627-635.
51. Bryant D., Becker L., Richardson J., et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 97:1997;1375-1381.
52. Bristow M.R. Tumor necrosis factor-alpha and cardiomyopathy. Circulation. 97:1998;1340-1341.
53. London B, Baker LC, Kubota T, et al. Slow conduction of premature beats leads to ventricular tachycardia in a TNF alpha transgenic model of congestive heart failure (abstr). Circulation 1999; In press.
54. Li YY, Feng YQ, Kadokami T, McTiernan CF, Feldman AM. Modulation of matrix metalloproteinase activities remodels myocardial extracellular matrix in TNF alpha transgenic mice (abstr). Circulation 1999. In press.
55. Kubota T., Miyagishima M., Bounoutas G.S., McTiernan C.F., Feldman A.M. Overexpression of tumor necrosis factor-alpha activates the expression of multiple members of the apoptosis pathway in transgenic mice. Circulation. 98:1998;I462.
56. Kubota T., Bounoutas G.S., Miyagishima M., McTiernan C.F., Feldman A.M. Development of myocarditis in transgenic mice overexpressing tumor necrosis factor alpha is mediated in part by the selective induction of downstream proinflammatory cytokines and beta-chemokines. Circulation. 98:1998;I345.
57. Bounoutas G.S., Kubota T., Miyagishima M., et al. Adenoviral-directed overexpression of soluble tumor necrosis factor receptors reverses myocarditis in transgenic mice with congestive heart failure (abstr). Circulation. 98:1998;I737.
58. Kapadia S., Torre-Amione G., Yokoyama T., Mann D.L. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. Am J Physiol. 268:1995;H517-H525.
59. Kolls J., Peppel K., Silva M., Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci USA. 91:1994;215-219.
60. Wilson A.G., Symons J.A., McDowell T.L., di Giovine F.S., Duff G.W. Effects of a tumor necrosis factor (TNF alpha) promoter base transition on transcriptional activity. Br J Rheum. 33:1994;89.
61. Stuber F., Petersen M., Bokelmann F., Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med. 24:1996;381-384.
62. Wilson A.G., di Giovine F.S., Duff G.W. Genetics of tumor necrosis factor-alpha in autoimmune, infectious and neoplastic diseases. J Inflamm. 45:1995;1-12.
63. Kaijzel E.L., van Krugten M.V., Brinkman B.M., et al. Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med. 4:1998;724-733.
64. Wilson A.G., di Giovine F.S., Blakemore A.I.F., Duff G.W. Single base polymorphism in the human tumor necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genetics. 1:1992;353.
65. Messer G., Spengler U., Jung M.C., et al. Polymorphic structure of the tumor necrosis factor (TNF) locus an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced levels of TNF-beta production. J Exp Med. 173:1991;209-219.
66. Danis V.A., Millington M., Hyland V., Lawford R., Huang Q., Grennan D. Increased frequency of the uncommon allele of a tumor necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers. 12:1994;127-133.
67. McGuire W., Hill A.V.S., Allsopp C.E.M., Greenwood B.M., Kwjatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature. 371:1994;508-511.
68. Kubota T., McNamara D.M., McTiernan C.F., et al. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. Circulation. 97:1998;2499-2501.
69. Feldman A.M., McNamara D.M., Wagner D.R. AMPD1 gene mutation in congestive heart failure new insights into the pathobiology of disease progression. Circulation. 99:1998;1397-1399.
70. Newell C., Deisseroth A., Lopez-Berestein G. Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF alpha gene. J Leukoc Biol. 56:1994;27-35.
71. Snyder D.S., Unanue E.R. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol. 129:1982;1803-1805.
72. Beutler B., Krochin N., Milsark I.W., Luedke C., Cerami A. Control of cachectin (tumor necrosis factor) synthesis mechanisms of endotoxin resistance. Science. 232:1986;977-980.
73. Arzt E., Sauer T., Pollmacher T., et al. Glucocorticoids suppress interleukin-1 receptor antagonist synthesis following induction by endotoxin. Endocrinology. 134:1994;672-677.
74. Yoshimura T., Kurita C., Nagoa T., et al. Inhibition of tumor necrosis factor-alpha and interleukin-1 beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology. 54:1997;144-152.
75. Szabo C., Hasko G., Zingarelli B., et al. Isoproterenol regulates tumor necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxemia. Immunology. 90:1997;95-100.
76. Vanderpoll T., Coyle S.M., Barbosa K., Braxton C.C., Lowry S.F. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest. 97:1996;713-719.
77. Shioi T, Matsumori A, Matsui S, Sasayama S. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci 1994;54:PL11-6.
78. Matsumori A., Shioi T., Yamada T., Matsui S., Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 89:1994;955-958.
79. Sliwa K., Skudicky D., Candy G., Wisenbaugh T., Sareli P. Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet. 351:1998;1091-1093.
80. Zabel P., Wolter D.T., Schonharting M.M., Schade U.F. Oxpentifylline in endotoxaemia. Lancet. 23:1989;1474-1477.
81. Bergman M.R., Holycross B.J. Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors (published erratum appears in J Pharmacol Exp Ther 1997;280:520). J Pharmacol Exp Ther. 1996;247-254.
82. Matsumori A., Ono K., Nishio R., Nose Y., Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells. A possible mechanism for its effect in heart failure. Circulation. 96:1997;1386-1389.
83. Matsumori A., Ono K., Nishio R., et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation. 96:1997;1501-1506.
84. Corral L.G., Muller G.W., Moreira A.L., et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med. 2:1996;506-515.
85. Ammann P., Rizzoli R., Bonjour J.P. Transgenic mice expressing soluble tumor necrosis factor are protected against bone loss caused by estrogen deficiency. J Clin Invest. 99:1997;1699-1703.
86. Wagner D.R., Combes A., McTiernan C.F., Sanders V.J., Feldman A.M. Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-alpha. Circ Res. 82:1998;47-56.
87. Wagner D.R., McTiernan C.F., Frye C.S., Lemster B.H., Feldman A.M. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation. 97:1998;521-524.
88. Sajjadi F.G., Takabayashi K., Foster A.C., Domingo R.C., Firestein G.S. Inhibition of TNF-alpha expression by adenosine role of A3 adenosine receptors. J Immunol. 156:1996;3435-3442.
89. Loh E., Rebbeck T.R., Mahoney P.D., DeNofrio D., Swain J.L., Holmes E.W. Common variant in the AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation. 99:1998;1422-1425.
90. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachetin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:1985;869-871.
91. Opal S.M., Cross A.S., Kelly N.M., et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis. 161:1990;1148-1152.
92. Sherry B.A., Gelin J., Fong Y., et al. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J. 3:1989;1956-1962.
93. Piguet P.F., Grau G.E., Vesin C., Loetscher H., Gentz R., Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with antitumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology. 77:1997;510-514.
94. Stokkers P.C., Camoglio L., van Deventer S.J. Tumor necrosis factor (TNF) in inflammatory bowel disease gene polymorphisms, animal models and potential for anti-TNF therapy. J Inflamm. 47:1996;97-103.
95. Kojouharoff G., Hans W., Obermeier F., et al. Neutralization of tumor necrosis factor (TNF), but not of IL-1, reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol. 107:1997;353-358.
96. Havell E.A. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol. 143:1989;2894-2899.
97. Kindler V., Sappino A.P., Grau G.E., Piguet P.F., Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 56:1989;731-740.
98. Moreland L.W., Baumgartner S.W., Schiff M.H., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 337:1997;141-147.
99. Deswal A., Seta Y., Blosch C.M., Mann D.L. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNPF:Fc) in patients with advanced heart failure (abstract). Circulation. 1998;I323.
100. Bozkurt B., Torre-Amione G., Soran O., et al. Results of a multidose phase I trial with tumor necrosis factor receptor (p75) fusion protein (Etanercept) in patients with heart failure (abstract). J Am Coll Cardiol. 1999;184A-185A.